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ABSTRACT
Associations between per- and polyfluoroalkyl substances (PFASs) and increased blood lipids have
been repeatedly observed in humans, but a causal relation has been debated. Rodent studies show
reverse effects, i.e. decreased blood cholesterol and triglycerides, occurring however at PFAS serum lev-
els at least 100-fold higher than those in humans. This paper aims to present the main issues regarding
the modulation of lipid homeostasis by the two most common PFASs, PFOS and PFOA, with emphasis
on the underlying mechanisms relevant for humans. Overall, the apparent contrast between human
and animal data may be an artifact of dose, with different molecular pathways coming into play upon
exposure to PFASs at very low versus high levels. Altogether, the interpretation of existing rodent data
on PFOS/PFOA-induced lipid perturbations with respect to the human situation is complex. From a
mechanistic perspective, research on human liver cells shows that PFOS/PFOA activate the PPARa path-
way, whereas studies on the involvement of other nuclear receptors, like PXR, are less conclusive.
Other data indicate that suppression of the nuclear receptor HNF4a signaling pathway, as well as per-
turbations of bile acid metabolism and transport might be important cellular events that require fur-
ther investigation. Future studies with human-relevant test systems would help to obtain more insight
into the mechanistic pathways pertinent for humans. These studies shall be designed with a careful
consideration of appropriate dosing and toxicokinetics, so as to enable biologically plausible quantita-
tive extrapolations. Such research will increase the understanding of possible perturbed lipid homeosta-
sis related to PFOS/ PFOA exposure and the potential implications for human health.
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1. Introduction
Per- and polyfluoroalkyl substances (PFASs) are man-made
substances with unique physicochemical properties, such as
oil and water repellence, high temperature and chemical
resistance, and emulsifying/surfactant properties. Because of
these properties, PFASs have been in use since the 1950s for
a wide range of industrial and consumer applications, includ-
ing food contact materials, water-repellent fabrics, waxes,
fire-fighting foams, shampoos and cosmetics, as well as insec-
ticides. Several long-chain PFASs, including the well-known
perfluorooctanoic acid (PFOA) and perfluorooctane sulfonic
acid (PFOS), are extremely persistent in the environment and
tend to bioaccumulate (OECD 2015). Measurable blood con-
centrations of PFOA and PFOS, and to a lesser degree other
PFASs, have been found in populations worldwide (US EPA
2016a, 2016b; Ballesteros et al. 2017; ATSDR 2018; EFSA
CONTAM Panel 2018a, 2020). Moreover, this class of substan-
ces has been associated with various adverse health effects
in humans, including serum lipid perturbations, immunotoxic-
ity, and developmental toxicity (US EPA 2016a, 2016b; ATSDR
2018; EFSA CONTAM Panel 2018a, 2020).
Despite agreements to phase out the production of cer-
tain PFASs by industry, part of the European population is
still exposed to levels of PFASs1 exceeding the tolerable
weekly intake (TWI) recently proposed by the EFSA CONTAM
Panel (2020), based on effects in humans. Furthermore, alter-
native PFASs are increasingly being used without sufficient
knowledge on their potential hazards and sources of emis-
sions. Thus, PFASs are a public health concern deserving
attention from health authorities and policy makers.
One of the human health concerns associated with PFAS
exposure is potential perturbation of triglyceride (TG) and
cholesterol homeostasis. PFASs, have been repeatedly found
to be positively associated with increased blood cholesterol
concentrations, and in some cases TGs, in numerous human
epidemiological studies. Increased serum cholesterol (total
cholesterol of >5.2mmol/L, i.e. >200mg/dL) (Leritz et al.
2016; Piepoli et al. 2016; Ference et al. 2017), and in particu-
lar its low density lipoprotein (LDL) fraction, is a well-estab-
lished risk factor for cardiovascular disease (CVD), including
ischemic heart disease and ischemic stroke (Piepoli et al.
2016; Ference et al. 2017; Boren et al. 2020). The use of chol-
esterol-lowering drugs such as statins has been shown to
decrease the risk of CVD (Piepoli et al. 2016; Ference et al.
2017). Moderate hypertriglyceridemia (>1.5mmol/L) is also
considered a CVD risk factor, albeit with a smaller correlation
when compared to the correlation between hypercholesterol-
emia and CVD (Nordestgaard and Varbo 2014; Piepoli et al.
2016; Sandesara et al. 2019). Consequently, even a small
increase in serum lipids caused by PFASs can be considered
a potential human health hazard.
In contrast to the evidence from human data, rodent stud-
ies with PFASs, commonly performed with high doses, have
demonstrated decreased serum cholesterol and TG levels,
accompanied by increased intrahepatic lipid (mainly TG) con-
centrations (Seacat et al. 2003; Loveless et al. 2006; Curran
et al. 2008; DeWitt et al. 2009; NTP 2019a, 2019b). Next to
this, liver toxicity is one of the most frequently reported
effects manifested as hypertrophy, steatosis, and in some
cases, even necrosis (RIVM 2018; NTP 2019a, 2019b). The
divergent results regarding blood lipids between rodents and
humans raise debate about the human relevance of rodent
data on lipid perturbation, but also about the causality of the
human findings on PFAS-associated elevated serum lipids
(EFSA CONTAM Panel 2018b).
Despite the fact that perturbed lipid homeostasis associ-
ated with PFAS exposure has received substantial attention,
clear understanding of the mechanisms involved in both ani-
mals and humans, is still lacking. This is partly due to distinct
species differences, pertaining to the combination of toxicoki-
netics and toxicodynamics, which have obscured the evalu-
ation of causal pathways and their interpretation in the
context of human health. Additionally, many studies focused
on peroxisome proliferator-activated receptor alpha (PPARa)-
mediated mechanisms, and less attention has been given to
other possible mechanisms explaining the observed effects,
such as interactions with other transcription factors.
The goal of the present paper is to present the state of
the art knowledge on the disturbance of cholesterol and TG
homeostasis by PFASs, and to bring forward the most
important issues pertaining to this topic. Possible explana-
tions for the findings and discrepancies observed between
different lines of evidence are identified, with an emphasis
on the underlying mechanisms, especially those that could
be relevant for humans. Elucidating the mechanism through
which PFASs might induce lipid perturbations would assist in
explaining the epidemiological findings, as well as establish-
ing the human relevance of experimental data. For this pur-
pose, this review presents i) a summary of the main findings
on PFAS-mediated lipid dysregulation, as recorded in epi-
demiological and animal studies, ii) an overview of the most
important related mechanistic knowledge, as derived from
mechanistic rodent studies and in vitro human-relevant test
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systems, and iii) the importance of PFAS species-specific toxi-
cokinetics. The aim of the work is neither to perform a sys-
tematic review nor to evaluate the quality and reliability of
all available data, since this has been previously performed
(EFSA CONTAM Panel 2018a, 2020), and hence, information
used is mainly derived from studies that are highlighted in
existing reviews and reports published by various agencies
(RIVM 2018; EFSA CONTAM Panel 2018a, 2020; Pizzurro et al.
2019), complemented with some recent scientific publica-
tions. The focus is on the two main congeners of the PFAS
group, PFOS (Figure 1, left) and PFOA (Figure 1, right).
Furthermore, this paper provides some recommendations on
how to address the identified issues and fill the knowledge
gaps, and lays down important factors that require careful
consideration when designing new studies. Altogether, this
paper aims to contribute to a better understanding of PFAS-
mediated lipid perturbations and the issues involved in their
interpretation for human health risk assessment.
2. PFOS and PFOA: lipid homeostasis perturbations
2.1. Effects observed in human studies
Both, PFOS and PFOA (further referred to as “PFOS/PFOA”
and/or PFASs), have been repeatedly found to be positively
associated with increased blood cholesterol concentrations in
multiple human epidemiological studies (EFSA CONTAM
Panel, 2018a). A few examples, which are representative for
these findings, are shown in Table 1. The epidemiological evi-
dence mainly comprises cross-sectional associations between
serum PFOS/PFOA and increased levels of cholesterol in
blood, with a few examples of longitudinal studies (EFSA
CONTAM Panel 2018a). Most studies have used general popu-
lation samples with the “normal” range of PFOS/PFOA con-
centrations for that country at that time (Nelson et al. 2010;
Eriksen et al. 2013; Geiger et al. 2014; Starling et al. 2014)
and some have used specific populations with occupational
exposure (Olsen et al. 2003; Sakr et al. 2007a; Sakr et al.
2007b) or contaminated community drinking water supplies
(Steenland et al. 2009; Frisbee et al. 2010; Canova et al. 2020;
Li et al. 2020). Exposure to the chemicals was in general for
several decades. In the majority of these studies, the general
pattern observed was a significant increase in the total serum
cholesterol or low density lipoprotein cholesterol (LDL-C)
associated with increased blood levels of PFOS and/or PFOA,
while the results reported for high density lipoprotein choles-
terol (HDL-C) were inconsistent. For the general population
studies, the magnitude of the increase in total serum choles-
terol, based on highest versus lowest quantiles, was around
5% (Steenland et al. 2009: PFOS þ6.4%, PFOA þ5.5%; Nelson
et al. 2010: PFOS þ6.8%; Eriksen et al. 2013: PFOS þ4.9%,
PFOA þ5.6%; Li et al. 2020: PFOA, PFOS þ7–9%), which may
correspond to a clinically relevant increase in the risk of CVD
(Piepoli et al. 2016; Ference et al. 2017).
The largest study is on 46 000 adults from the C8 cohort
in the mid-Ohio valley, in which residents were exposed for
many decades to various PFOA levels through contaminated
drinking water and via food, and show a wide range of
serum concentrations (Steenland et al. 2009). This study
showed median blood PFOS and PFOA levels of 20 and
27 ng/mL, respectively. Notably, for PFOA very high blood
levels (up to 18 000 ng/mL) were observed in part of the
population. Much of the increase is observed at low PFOS/
PFOA serum levels and seems to level off at higher levels
(above about 50 ng/mL), as also shown by the modeling of
the data (EFSA CONTAM Panel 2018a). Another large popula-
tion with PFAS exposure from contaminated drinking water,
predominantly PFOA, is in the Veneto region of Italy (Canova
et al. 2020). A cross sectional analysis of PFASs and lipids was
carried out in nearly 16 000 people, between 20 and 39 years.
The median PFOA serum concentration was 35.8 ng/ml, and
the pattern broadly consistent with the C8 study, i.e. increas-
ing cholesterol with PFOA concentration and a steeper slope
at lower concentrations. Another recent study on a commu-
nity, living in a PFAS-polluted area and exhibiting raised
serum levels of mainly PFOS (and other PFASs) and to a
lesser degree PFOA, also reported positive associations with
serum cholesterol (Li et al. 2020). In addition to the cross-sec-
tional analyses associating concurrent serum measurements
of PFASs and lipids, the authors included an ecological com-
ponent showing higher cholesterol in the exposed commu-
nity compared to subjects sampled in a nearby, non-
exposed community.
In contrast to the community studies, the reported magni-
tude of the effect on cholesterol is lower in workers at much
higher serum concentrations, e.g. aþ 2–3% increase in chol-
esterol per increase in serum PFOA levels of 1000 ng/mL
(Sakr et al. 2007b) with exposure for several years and higher
serum concentrations of PFOS/PFOA (mean or median levels
1000 ng/mL, PFOA: 7–92 300 ng/mL, PFOS: 20–6240 ng/mL)
(Olsen et al. 2003; Olsen et al. 2007; Sakr et al. 2007a; Sakr
et al. 2007b). Olsen and Zobel (2007) re-analyzed the data
from 2003 (Olsen et al. 2003) and after some exclusions, e.g.
people using cholesterol lowering drugs, no longer observed
an association between PFOS/PFOA and total cholesterol and
LDL-C. Positive associations between increased serum levels
of TGs and PFOS and/or PFOA were also recorded in both
workers and the general population, but in relatively few
studies (Olsen et al. 2003; Olsen and Zobel 2007; Steenland
et al. 2009).
Figure 1. Chemical structure of PFOS (left) and PFOA (right).
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Although the associations between serum levels of total
cholesterol, LDL-C and TGs and serum levels of PFOS/PFOA
have been recorded repeatedly, the causality of these expos-
ure-effect relationships is still an issue requiring further scien-
tific inquiry (EFSA CONTAM Panel 2020). In addition, the
available evidence for an association between PFOS/PFOA
exposure and an associated adverse outcome, i.e. CVD, is
missing (EFSA CONTAM Panel 2020).
An important limitation of most of the studies, is that they
were cross-sectional in design, and so the direction of causal-
ity is unknown and may be vulnerable to confounding affect-
ing serum concentrations of both PFOS/PFOA and
cholesterol. An example of potential confounding is related
to the enterohepatic cycling of PFOS/PFOA and bile acids.
PFOS/PFOA have been shown to be excreted to the bile and
it was estimated that thereafter, most of the PFOS/PFOA
must undergo extensive enterohepatic re-absorption from
the gastrointestinal tract to explain the long half-lives in
humans (Harada et al. 2007; Fujii et al. 2015) (see Section 4).
In line with this, absorption of PFOS/PFOA was shown to be
mediated by the transporters that also participate in absorp-
tion of bile acids (Zhao et al. 2015). Given that differences in
the absorption of bile acids due to genetic factors, such as
interindividual variations, food composition or medicines can
result in altered levels of serum cholesterol, it is plausible
that confounding related to excretion and re-absorption in
the enterohepatic cycling process may play a role in the
cross-sectional associations observed for PFOS/PFOA and
total serum cholesterol (EFSA CONTAM Panel 2020).
A few studies had a longitudinal design (see example in
Table 1), and as such were subject to a smaller risk of con-
founding. For example, in a longitudinal study within the C8
cohort, the incidence of the diagnosis of increased serum
cholesterol levels was related to the modeled serum PFOA in
the population. The exposure model was based on the water
concentrations and intake, not individual measurements, and
thus was not vulnerable to the confounding described above.
A modest, but significant, increase of serum cholesterol levels
in relation to modeled PFOA intake was found (Winquist and
Steenland 2014). The same study assessed CVD in relation to
PFOA and did not find an association. A subgroup of subjects
in the C8 study participated in a longitudinal follow-up study
with repeated blood testing about 4 years after the first sur-
vey (Fitz-Simon et al. 2013), showing a general decline of
serum PFOS/PFOA levels by an average of about 60% reflect-
ing the half-life of approximately 3 years. The mean total
cholesterol level did not fall, but was slightly increased,
which may be explained by increasing age or change in life-
style. When stratifying the group according to the extent of
decrease in serum PFOS or PFOA levels, it was shown that
those with the highest decrease in PFOS/PFOA showed a
relative decrease in serum cholesterol levels, compared to
the group with the lowest decrease in PFOS/PFOA. These
results also suggest that the effect of PFOS/PFOA on choles-
terol levels is reversible. The similarity in the direction of
results across different study designs (cross sectional, eco-
logic and longitudinal) supports a causal role for PFOA in
increasing cholesterol. On the other hand, one would expect
an exposure-related increase in cardiovascular risk, but there
is little evidence for this.
A recently published human study (Convertino et al. 2018)
does not seem to support the findings regarding increased
cholesterol, as observed in a large number of epidemiological
studies. This was a clinical phase 1 dose-escalation study with
49 cancer patients, who were administered for 6weeks very
high doses of PFOA, resulting in serum levels of
150 000–230 000 ng/mL (Table 1). The authors reported a sub-
sequent dose-dependent reduction in total cholesterol and
LDL-C levels in blood. However, this study is probably of little
relevance for the general and worker population, since it was
conducted in a small population of late-stage cancer patients,
whose metabolic activity may differ considerably from
healthy individuals. In addition, high doses of PFOA were
applied for a limited time period.
In parallel to cholesterol changes, an increased incidence
of mildly elevated serum levels of the liver enzyme alanine
transferase (ALT) associated with PFOA exposure was
recorded (Lin et al. 2010; Gallo et al. 2012; Darrow et al.
2013; Gleason et al. 2015; Salihovic et al. 2018; Jain and
Ducatman 2019; Nian et al. 2019). Some studies reported
similar findings for PFOS (Lin et al. 2010; Gallo et al. 2012;
Salihovic et al. 2018). Nevertheless, the magnitude of the
associations between serum ALT and PFOA (and PFOS) levels
was small (3%). In addition, the observed changes in ALT
were not accompanied by observable adverse health effects,
such as liver damage and metabolic disorders (EFSA CONTAM
Panel 2018a, 2020).
2.2. Effects observed in animal toxicity studies
The interpretation of perturbations in lipid homeostasis
observed in human studies becomes more challenging
when considering the apparent lack of similar effects in
rodent models. In fact, rodent data in general demon-
strate opposite findings, i.e. a hypolipidemic effect char-
acterized by decreased levels of serum cholesterol
(20–40%) and TGs (30–80%) after exposure to PFOS/
PFOA. Some representative studies are presented in
Table 2. It should be noted that the purpose of this
manuscript is not to perform a comprehensive review;
thus, Table 2 lists only examples of typical studies. In
rodents, decreases in serum cholesterol and TGs have
been observed after repeated exposure (starting already
at exposure durations of 2–4 weeks) and at doses
between 0.3 and 10mg/kg bw/d, which resulted in serum
levels of 50 000–500 000 ng/mL (Loveless et al. 2006;
Curran et al. 2008; DeWitt et al. 2009; Minata et al. 2010;
Bijland et al. 2011; Yan et al. 2015; NTP 2019a, 2019b;
see some information in Table 2). These PFAS serum lev-
els are much higher than those levels associated with
increased serum lipids in humans (observed at mean
serum concentrations as low as 20–30 ng/mL; Table 1).
For PFOS, decreases in serum cholesterol were also
reported after longer exposure durations (13–14 weeks)
(Seacat et al. 2003; Butenhoff et al. 2012), whereas for
PFOA these endpoints were not examined in longer-term
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studies (Perkins et al. 2004; Butenhoff et al. 2012). Very
few investigations in animals used PFOS/PFOA doses that
were low enough to have given serum concentrations
like those seen in humans. At these low exposure levels,
serum lipids were not affected by PFOS/PFOA treatment
in rodents (Seacat et al. 2003; Yan et al. 2015; Pouwer
et al. 2019). Nevertheless, only one of these studies illus-
trates a dose–response (Pouwer et al. 2019), discussed
Table 1. Representative human studies reporting associations between serum levels of PFOS and/or PFOA and serum levels of lipids.
Substance
Study information, No
of subjects Findings in serum Serum levels (ng/mL) Reference
Cross-sectional studies general population
PFOS/PFOA Denmark DCH, 753
individuals
PFOS vs TC " Mean PFOS 36,
Mean PFOA 7.1
Eriksen et al. (2013)
PFOA vs TC "
PFOS/PFOA NHANES, USA, 860 adults PFOS vs TC " Median PFOS 20, Median
PFOA 3.8
Nelson et al. (2010)
PFOS vs non-HDL-C "
PFOS vs LDL-C "
PFOA vs TC "
PFOA vs non-HDL "
PFOA vs LDL-C "
PFOS/PFOA C8 cohort, 46 000 adults PFOS vs TC " Median PFOS 20 Steenland et al. (2009)
PFOS vs LDL-C "
PFOS vs TGs "
PFOA vs TC " Median PFOA 27
PFOA vs LDL-C "
PFOA vs TGs "
PFOS/PFOA
C8 cohort, 12 500,
children, 1–18 y
PFOS vs TC " Mean PFOS 23 Frisbee et al. (2010)
PFOS vs LDL-C "
PFOS vs HDL-C "
PFOA vs TC " Mean PFOA 69
PFOA vs LDL-C "
PFOA vs HDL-C "
PFOS/PFOA Sweden, 1945 adults† PFOS vs TC " Median PFOS 157 Li et al. (2020)
PFOS vs LDL-C "
PFOA vs TC " Median PFOA 8.6
PFOA vs LDL-C "
Cross-sectional studies occupational settings
PFOS/PFOA USA (3M), and Belgium, 518
individuals
PFOS vs TC " High, mean PFOS and PFOA
about 1000
Olsen et al. (2003)
PFOS vs TGs "
PFOA vs TC "
PFOA vs TGs "
PFOA USA (3M) and Belgium, 506
individuals (re-evaluation of
2003 data)
PFOA vs HDL-C #




Olsen and Zobel (2007)
PFOA vs TGs "
PFOA USA (DuPont), 1025
individuals
PFOA vs TC
High, median PFOA 114–494
across 4 categories
(range 8–9550)
Sakr et al. (2007a)
PFOA vs LDL-C "
PFOA vs VLDL-C "
Longitudinal studies general population
PFOS/PFOA C8 cohort, 560 individuals PFOS vs TC " Geometric Mean PFOS: from
10 to 8
Fitz-Simon et al. (2013)
PFOS vs LDL-C "
PFOA vs TC " Geometric Mean PFOA: from
75 to 31PFOA vs LDL-C "
PFOA C8 cohort, 32 000 individuals,
general population
and workers
PFOA vs TC" Median PFOA general
population 24 and workers
113. Modeled cumulative
PFOA: 20th percentile 215 ng/
mLyear and 80th percentile
1820 ng/mLyear
Winquist and Steenland (2014)
Longitudinal studies occupational settings
PFOS/PFOA USA (3M), and Belgium, 174
individuals
PFOA vs TC " High, mean PFOS and PFOA
about 1000
Olsen et al. (2003)
PFOA vs TGs "
PFOA USA (DuPont), 454 individuals PFOA vs TC " High, mean PFOA about 1000 Sakr et al. (2007b)
Therapeutic studies
PFOA




PFOA vs TC #
150 000–230 000
Convertino et al. (2018)
PFOA vs LDL-C #
Only significant positive or inverse (negative) associations are mentioned in the Table. However, some studies showed also negative findings (no associations).
†Municipality where one out of two waterworks had been heavily contaminated from aqueous fire-fighting foams, and from a nearby control area.
DCH: Diet Cancer and Health; C8: study performed in the “C8” area where drinking water was contaminated by PFOA from a DuPont plant; “"” sign illustrates a
statistically significant positive association; “#” sign illustrates inverse a statistically significant association; TC: total cholesterol; TGs: triglycerides; LDL-C: low-
density lipoprotein; HDL-C: high-density lipoprotein.
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Table 2. Example studies in animals reporting on lipid perturbations induced by PFOS/PFOA. Only induced effects are reported in the table.
Substance Experimental design
Lipid perturbation-






PFOS Sprague Dawley rats
(m,f),
4 weeks, in feed
0, 0.14, 1.33, 3.21,
6.34 (m)
0, 0.15, 1.43, 3.73,
7.58 (f) mg/kg bw/d
# serum TC (m) 3.21 20.93 ± 2.36 856.90 ± 353.83 Curran et al. (2008)
# serum TGs (m) 3.21 20.93 ± 2.36 856.90 ± 353.83
# serum TC (f) 3.73 31.93 ± 3.6 597 ± 158
# serum TGs (f) 3.73 31.93 ± 3.6 597 ± 158
PFOS Sprague Dawley rats
(m,f), 4 weeks,
gavage
0, 0.312, 0.625, 1.25,
2.5, 5mg/kg bw/d
# serum TC (m) 0.312 23.73 ± 1.11 87.17 ± 3.03 NTP (2019a)
# serum TGs (m) 5 318.2 ± 8.86 867.1 ± 26.8
# serum TC (f) 5 413.55 ± 8.07 NR
# serum TGs (f) 2.5 237.5 ± 5.218 NR
PFOS Sprague Dawley rats
(m,f), 14 weeks, feed
0, 0.05, 0.2, 0.4,
1.5mg/kg bw/d
# serum TC (m) 1.5 148 ± 14 568 ± 107 Seacat et al. (2003)
PFOA Sprague Dawley rats
(m), 2 weeks,
gavage
0, 0.3, 1, 3, 10,
30mg/kg bw/d
# serum TC 0.3 20 ± 3.2 NR Loveless
et al. (2006)# serum TGs 0.3 20 ± 3.2
# non-HDL-C 0.3 65 ± 11
# HDL-C 3 137 ± 18
PFOA Sprague Dawley rats
(m,f), 4 weeks,
gavage
0, 0.625, 1.25, 2.5, 5,
10 (m) mg/kg bw/d
0, 6.25, 12.5, 25, 50,
100 (f) mg/kg bw/d
# serum TC (m) 0.625 50.69 ± 2.2 54.61 ± 2.23 NTP (2019b)
# serum TGs (m) 0.625 50.69 ± 2.2 54.61 ± 2.23
" serum TC (f) 50 9.32 ± 1.82 NR
" serum TGs (f) 50 9.32 ± 1.82 NR
Studies in mice
PFOS CD-1 mice (m),
3,7,14,21 days,
gavage
0, 1, 5, 10mg/kg bw
# serum TC 5 NR NR Wan et al. (2012)
# serum VLCL-C 5
# serum LDL-C 5
" liver lipids 5
PFOA SV129 mice (m),
7 days, gavage
0, 10mg/kg bw
" liver lipids 10 NR NR Das et al. (2017)





" liver lipids 5 NR NR Tan et al. (2013)
PFOA Crl:CDVR -1(ICR)BR
mice (m), 2 weeks,
gavage
0, 0.3, 1, 3, 10,
30mg/kg bw/d
# serum TC 3 69 ± 10 NR Loveless






# serum TC 10.8 46.9 ± 3.2 198.8 ± 15.4 Minata et al. (2010)






" serum TC (f,
C56BL/6)
0.5 8.6 NR Rebholz et al. (2016)
" serum TC (m,
C56BL/6)
26.9
" serum TC (m,
BALB/c)
28.2
# liver TC (m.f
BALB/c)
PFOA BALB/c mice (m),
4 weeks, gavage
0, 0.08, 0.31, 1.25, 5,
20mg/kg bw/d
# liver TC 0.31 NR (Yan et al. 2015)






# serum TC 3 86–125 (mean range
from 3 experiments)
NR Bijland et al. (2011)
# serum TGs 3 86–125
# serum non-HDL-C 3 86–125
# serum HDL-C 3 86–125
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further in Section 3.1.2, whereas only a single dose level
was applied in the other two.
Most investigations on the effects of PFOS/PFOA have
been performed in rats and mice, with a few exceptions, in
which monkeys have been used (examples in Table 2). PFOS
lowered the serum cholesterol in cynomolgus monkeys after
repeated exposure, when administered at doses comparable
to those in the high dose rodent studies (serum:
15 000–70 000 ng/mL) (Seacat et al. 2002; Chang et al. 2017).
A 6-month oral PFOA administration in monkeys (serum:
70 000–160 000 ng/mL) produced a mild increase in circulat-
ing TGs, whereas blood cholesterol appeared unaffected
(Butenhoff et al. 2002).
In parallel to the hypolipidemic effects in the blood, other
lipid disturbances observed include enhanced intrahepatic
accumulation of lipids, mainly TGs, in rodents for both PFOS
(Bijland et al. 2011; Wan et al. 2012; Wang et al. 2014), and
PFOA (Nakagawa et al. 2012; Tan et al. 2013; Wang et al.
2013; Das et al. 2017; Hui et al. 2017; Wu et al. 2018;
Schlezinger et al. 2020) (see Table 2 for examples). The liver
appears to be a major target organ for both compounds in
rats and mice, as indicated by increased liver weight, hyper-
trophy of centrilobular hepatocytes, induction of peroxisomal
and mitochondrial ß-oxidation, and in some cases necrosis.
Liver damage in rodents is also indicated by increased serum
transaminases (Curran et al. 2008; Son et al. 2008; Yu et al.
2009; Elcombe et al. 2012; NTP 2019a, 2019b). Similarly, in
primates the liver appears to be a target organ for PFOS/
PFOA, with effects manifested as increased liver weights with
hepatocellular hypertrophy and vacuolation (Butenhoff et al.
2002; Seacat et al. 2002; Chang et al. 2017). It has been
speculated that the observed liver damage, like steatosis and
necrosis, can be attributed to the alterations in the hepatic
lipid metabolism (EFSA CONTAM Panel 2020).
2.3. Interpretation of human versus rodent data
Several population studies have repeatedly found correlations
between increased blood levels of PFOS/PFOA and elevated
blood total cholesterol and LDL-C, (and to a lesser extent
TGs). Nevertheless, these findings have not been linked to a
corresponding adverse health effect and are inconsistent
with toxicological animal studies, where high doses of PFOS/
PFOA were found to lower serum cholesterol and TGs, and















# serum TGs 3.2 90–150 NR Pouwer et al. (2019)
# serum TC 3.2 90–150
# non-HDL 3.2 90–150
" HDL-C 3.2 90–150
PFOS WT and PPARa null
mice (m), 7 days





10 NR NR Rosen et al. (2010)
PFOA hPPARa mice,
6weeks, gavage
0, 1, 5mg/kg bw/d
# serum TGs 1 NR NR Nakagawa
et al. (2012)" liver TGs 1














# serum TC (m) 0.03 15.8 ± 1.4 17.3 ± 4.7 Seacat et al. (2002)
# serum TGs (m) 0.15 82.6 ± 25.2 58.8 ± 19.5
# serum HDL-C 0.03 15.8 ± 1.4 17.3 ± 4.7
" liver lipids (m) 0.75 173 ± 37 395 ± 24
# serum TC (f) 0.75 171 ± 22 273 ± 14
# serum HDL-C 0.75 171 ± 22 273 ± 14












# serum TC (m) NR 74 NR Chang et al. (2017)
# serum HDL-C 74
# serum TC (f) 76
# serum HDL-C 76
m: males; f: females; bw: body weight; NR: not reported; TC: total cholesterol; HDL-C: high-density lipoprotein cholesterol; TGs: triglycerides; hPPARa: human per-
oxisome proliferator-activated receptor; WT: wild-type; “"” sign illustrates a statistically significant increase; “#” sign illustrates a statistically significant decrease.
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present the health risk assessors a conundrum.As noted
above, some representative studies on these findings are
described in Tables 1 and 2. For a complete picture of the
epidemiological and animal data the reader is referred to the
EFSA CONTAM Panel Opinions (2018a, 2020).
Considering the large differences in exposure levels
between humans and laboratory animals and in order to
facilitate the discussion, serum levels of PFOS/PFOA
together with externally administered doses are mentioned
here, when available. Furthermore, it should be highlighted
that not only PFOS/PFOA serum concentrations are of
importance in such evaluations, but also the related hep-
atic concentrations (also reported when available). A rela-
tively higher retention of PFOS/PFOA in the liver in one
species compared to another could also play a role in the
different outcomes.
Next to the exposure levels, exposure duration may also
be divergent, i.e. several decades for humans versus several
(2–14) weeks for animals2. Consequently, one could argue
that in humans, PFOS/PFOA chronic exposure leads to a dif-
ferent lipid response and balance, whereas this is not the
case for rats exposed for shorter periods. It cannot be
excluded that such differences may also contribute to the dif-
ferential responses between the two species. It shall be
noted here that irrespective of the shorter exposure duration,
data indicate that a serum steady-state concentration is also
reached in the rat for both compounds (Gomis et al. 2018).
Apart from the exposure levels and exposure duration,
other reasons are known or suspected to be implicated in
the observed differences, including differences in mecha-
nisms underlying the observed effects and in PFAS species-
specific toxicokinetics. An understanding of the causal path-
way that may lead from chemical exposure to potential
adverse outcomes could assist in a better understanding of
the epidemiological data. An overview of such mechanisms,
which may explain the PFOS/PFOA-mediated lipid disturban-
ces, is presented below. Information discussed stems from
mechanistic rodent studies (including genetically modified
mice) and in vitro test systems performed with human rele-
vant material, such as human hepatocytes. Next to this,
PFOS/PFOA species-specific toxicokinetics issues
are presented.
3. Mechanistic pathways involved in PFAS-induced
lipid perturbations
3.1. Species differences in lipoprotein homeostasis
3.1.1. General information on lipoprotein circulation
The liver is the primary organ tightly controlling lipid homeo-
stasis, in humans, as well as in other primates and rodents,
to ensure a balance between influx, generation, and efflux of
lipids. Main functions of the liver with respect to lipid
homeostasis include the fatty acid b-oxidation for energy
supply, cholesterol biosynthesis and lipogenesis. Circulation
of the lipids through the body occurs via specific carrier mol-
ecules, i.e. the lipoproteins, also synthetized in the liver
(Dietschy et al. 1993; Kwiterovich 2000) (Figure 2).
Lipoproteins contain a hydrophobic core comprising
cholesteryl-esters and TGs, and a amphipathic part, which
consists of apolipoproteins and phospholipids (Imes and
Austin 2013).
After a meal, the intestine releases chylomicrons,
which are mainly composed of TGs and to a lesser
extent cholesteryl-esters. Most of the TGs are cleared in
the adipose tissue and muscle through the action of
lipoprotein lipase. The leftover TGs and the cholesteryl-
esters are taken up by the liver as part of chylomicron
remnants (Figure 2). The liver uses the cholesterol to
synthesize bile acids, which together with cholesterol
are secreted into the bile. During fasting, the liver
serves as a sink for circulating adipose tissue-derived
free fatty acids, which are either fully oxidized or con-
verted into ketone bodies. In addition, incoming fatty
acids are esterified into TGs and stored within lipid
droplets or secreted as very low-density lipoproteins
(VLDL) for delivery of primarily TGs to the peripheral tis-
sues (Zhang et al. 2014). In the blood, VLDL are further
metabolized through the removal of the TG portion into
LDL, the latter being the main carrier of cholesterol to
many tissues including the liver, and taken up via the
LDL-receptor (LDLR). On the other hand, the HDL par-
ticles participate in the reverse cholesterol transport
pathway, i.e. acquiring excess cholesterol effluxed from
peripheral tissues and returning it to the liver. The main
apolipoprotein in VLDL and LDL particles is apolipopro-
tein B (apoB) and in HDL apolipoprotein A-I (apoA-I)
(Feingold 2000; Imes and Austin 2013; Marques et al.
2018). Disturbances in these metabolic pathways can
promote fatty-liver disease and lead to alterations in
plasma lipid levels (Adiels et al. 2008).
The above described processes comprise some general
characteristics of lipid homeostasis that overall are well-con-
served across species (Dietschy et al. 1993; Bergen and
Mersmann 2005). Nevertheless, several aspects of lipid homeo-
stasis are known to be specific for humans or rodents. These
include differences pertaining to lipoprotein metabolism
(Dietschy and Turley 2002; Princen et al. 2016), which ultim-
ately results in different proportions of the circulating lipopro-
teins amongst species (Bergen and Mersmann 2005; Lee-
Rueckert et al. 2016; Kaabia et al. 2018). Hence, in mice and
rats, serum cholesterol is for the major part confined to HDL,
while the levels of cholesterol carried by VLDL and LDL are
low. In contrast, in humans and non-human primates, the
majority of cholesterol is contained in the apoB-containing lip-
oproteins LDL and to a lesser extent VLDL, thereby resulting in
a higher proportion of LDL relative to HDL in the blood
(Krause and Princen 1998; Princen et al. 2016). This occurs due
to a faster LDL clearance pathway in rodents compared to
humans (Dietschy et al. 1993; Dietschy and Turley 2002), and
the complete absence of cholesteryl ester transfer protein
(CETP) in rats and mice. CETP is a central element in lipopro-
tein metabolism and is responsible for the transfer of choles-
teryl-esters from HDL to apoB-containing lipoproteins in
exchange for TGs (Chapman et al. 2010; Morton and Izem
2014; Princen et al. 2016). Consequently, the choice of the ani-
mal model should be carefully considered.
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3.1.2. Species differences in lipoprotein homeostasis in
relation to PFAS lipid-related effects
A few studies attempted to clarify the relevance of such spe-
cies-specific differences for the observed PFOS/PFOA lipid-dis-
turbing effects (Bijland et al. 2011; Pouwer et al. 2019). For
this, the genetically engineered mouse model APOE3-
Leiden.CETP (Westerterp et al. 2006) was used, which mimics
human lipoprotein metabolism and the response to clinically
used hypolipidemic drugs, such as statins, fibrates, niacin and
the novel PCSK9-inhibitors (Zadelaar et al. 2007; Ason et al.
2014; K€uhnast et al. 2015; Pouwer et al. 2020). At the two
highest doses tested, both PFOS (86 000–125 000 ng/mL,
4–6weeks) and PFOA (90 000–150 000 ng/mL, 4–6weeks)
induced hypolipidemia in the blood, which was characterized
by decreased levels of TGs (50–70%) and total cholesterol
(30–60%) (mainly the non-HDL fraction) (Bijland et al. 2011;
Pouwer et al. 2019). These findings are in line with other
studies with PFOS/PFOA conducted in wild-type mice and
rats, with similar dose levels and exposure durations.
However, in the wild-type animals the decrease in cholesterol
is presumed to be mainly due to the HDL fraction.
Unfortunately, most of the animal studies did not discrimin-
ate between the lipoproteins and mainly measured total
cholesterol. Concurrently, PFOS exposure enhanced intrahe-
patic TG and cholesterol concentrations in APOE3-
Leiden.CETP mice (Bijland et al. 2011), while such lipid
changes were not seen with PFOA at a similar dose (Pouwer
et al. 2019). Mechanistic studies revealed that the decreased
serum lipid levels occurred through PFOS/PFOA-enhanced
(lipoprotein lipase-mediated) VLDL-TG clearance and PFOS/
PFOA-decreased hepatic VLDL-TG and apoB production. The
observations were further supported by gene expression
alterations and pathway analysis confirming the changes in
lipoprotein metabolism measured (Bijland et al. 2011; Pouwer
et al. 2019). It should be noted that these effects were only
seen at doses and respective serum levels that are several
orders of magnitude higher than those relevant in humans
(Table 2), whereas they were absent at lower, human-relevant
environmental or occupational serum levels (50–2000 ng/mL);
only PFOA was tested at these low doses (Pouwer
et al. 2019).
These findings from the studies using the APOE3-
Leiden.CETP model indicate that the known differences in
lipoprotein metabolism between humans and rodents, as dis-
cussed above, cannot sufficiently explain the observed dis-
crepancy in PFOS/PFOA-induced lipid perturbations.
Although the APOE3-Leiden.CETP mouse has a humanized
lipoprotein metabolism, it does not integrate other species
differences that possibly play a fundamental role in the
respective lipid perturbations (see next sections). On the
other hand, the findings observed could be interpreted
otherwise, and one could hypothesize that substantial differ-
ences in serum PFOA concentrations (at least two or three
orders of magnitude) are indeed the main determinant of
the interspecies differences reported (the slight reduction in
cholesterol reported for cancer patients with very high serum
PFOA (Convertino et al. 2018) is consistent with this finding.
Perhaps at such high serum levels different pathways come
into play, both in humans and animals. Accordingly, exposure
to PFOA at low doses may not have a significant effect on
Figure 2. Overview of the lipid circulation throughout the human body with their carrier molecules, the lipoproteins. LPL: lipoprotein lipase; LDL: low-density lipo-
protein; VLDL: very low-density lipoprotein; TGs: triglycerides; ApoB: apolipoprotein B. Created with BioRender.com.
CRITICAL REVIEWS IN TOXICOLOGY 149
serum lipid homeostasis, as illustrated by the findings from
the APOE3-Leiden.CETP mouse. The resulting uncertainty
regarding the causality of the epidemiological observations
and PFOS/PFOA exposure could be reduced by further eluci-
dation of the mechanism(s) involved.
Additionally, when evaluating the different effects of
PFOS/PFOA on blood lipids between humans and rodents, it
is important to realize that rodent chow contains much less
fat and almost no cholesterol when compared to the high-fat
Western type diet of humans. For this reason, some studies
were performed with rodents fed with a more human-
relevant diet (Bijland et al. 2011; Wang et al. 2014; Rebholz
et al. 2016; Pouwer et al. 2019), in order to delineate whether
dietary factors are responsible for the absence of the
increased blood lipid effect of PFASs in rodents fed
conventionally.
Wang et al. (2014) treated BALB/c mice with PFOS com-
bined with a normal or high fat diet (Table 2). Indeed, in the
control animals, fed with the high-fat diet alone, a significant
increase in blood cholesterol (HDL and LDL), together with
an increase in hepatic fat content, was reported (Wang et al.
2014). Nevertheless, unlike the controls, the PFOS-treated
mice exhibited reduced levels of serum lipids and lipopro-
teins, independent of the dietary regimen. Administration of
a Western-type diet together with PFOS or PFOA was also
employed with the aforementioned studies on the APOE3-
Leiden.CETP mice (Bijland et al. 2011; Pouwer et al. 2019).
Similarly, blood cholesterol and TGs were decreased in PFOS
or PFOA-treated animals. These results suggest that the diet-
ary fat does not interfere with the PFOS/PFOA-induced lipid
perturbations observed in rodents. On the other hand, one
single study demonstrated different results, where C57BL/6
mice showed increased blood cholesterol (35% in males, 70%
in females), when receiving PFOA together with a choles-
terol/lipid-rich diet, in comparison to the animals treated
only with the lipid rich diet (Rebholz et al. 2016). A less pro-
nounced increase in blood cholesterol (20%) was seen in
male BALB/c mice, whereas blood cholesterol remained
unaffected in the PFOA-treated BALB/c female mice when
compared to control animals being on the high fat
diet alone. The increased cholesterol was contained in the
(large) HDL fraction, as expected for the rodents.
Unfortunately, only one dose level was applied, while a con-
trol group fed on standard chow was not included. Overall,
no conclusive differences were identified that can fully justify
the contrasting lipid disturbances in rodents versus humans
upon PFAS exposure; still, it cannot be excluded that diet
might play a role, but effects need to be further clarified.
3.2. The role of PPARa in PFOS/PFOA-induced lipid
perturbations
3.2.1. General information on the PPARa
The regulation of hepatic lipid and cholesterol metabolism
occurs largely at the level of gene transcription by nutrient-
sensitive transcription factors, encompassing several nuclear
receptors. One of the main nuclear receptors involved in the
regulation of hepatic lipid metabolism is PPARa, which is
primarily activated by fatty acids and various fatty acid deriv-
atives (G€ottlicher et al. 1992). The activation of PPARa in
rodent and human hepatocytes induces the expression of
numerous genes involved in various pathways of lipid metab-
olism, such as fatty acid storage, b-oxidation, and transport
(Kersten 2014; Kersten and Stienstra 2017). For example,
PPARa serves as direct molecular target of fibrate drugs,
which are used in the treatment of dyslipidemia and lower
blood lipid levels by inducing lipoprotein lipase-mediated
VLDL-TG clearance (Schoonjans et al. 1996; Chapman et al.
2010; Fabbrini et al. 2010; Kim and Kim 2020).
3.2.2. Lipid homeostasis and activation of PPARa by
PFOS/PFOA in rodents
PFOS/PFOA structurally resemble fatty acids and are well-
established ligands of PPARa in the rat and mouse liver
(Perkins et al. 2004; Wolf et al. 2008; Rosen et al. 2010;
Elcombe et al. 2012; Wolf et al. 2012, 2014; Rosen et al.
2017). Consequently, activation of the PPARa signaling path-
way upon exposure to PFOS or PFOA is believed to be, at
least partly, responsible for the observed perturbations of
lipid homeostasis in animals (DWQI 2017, 2018; EFSA
CONTAM Panel 2018a). In fact, gene expression studies con-
ducted on liver samples from PFOS/PFOA-exposed rodents
revealed that a substantial proportion of the up- or down-
regulated genes (e.g. Cyp4a1, Acox1) are under the control of
the PPARa receptor (Rosen, Abbott, et al. 2008; Ren et al.
2009; Rosen et al. 2010, 2017; Pouwer et al. 2019). In terms
of the PPARa activation potency, PFOA was shown to be
more potent when compared to PFOS, both in reporter gene
assays and in gene expression studies with rat hepatocytes.
(Takacs and Abbott 2007; Wolf et al. 2008; Bjork and Wallace
2009; Wolf et al. 2012). Also, in the recent NTP (2019a,
2019b) studies in male rats, PFOA appeared to be a more
potent inducer of Acox1 and Cyp4a1 gene expression in livers
than PFOS, despite a lower accumulation in liver.
As prototypical PPARa agonists, PFOS/PFOA induce the
mitochondrial and peroxisomal ß-oxidation of fatty acids for
their degradation to acyl-CoA-moieties in the rodent liver
(Rosen et al. 2010; Bijland et al. 2011; Wan et al. 2012; Wang
et al. 2014; Pouwer et al. 2019). Furthermore, they induce the
fatty acid transport across the mitochondrial membrane
(Rosen et al. 2010; Bijland et al. 2011; Wang et al. 2014;
Pouwer et al. 2019). In parallel, they decrease the hepatic
VLDL-TG and apoB production, disturbing as such the hepatic
secretion of TGs (and indirectly cholesterol) into the blood.
Furthermore, they promote lipoprotein lipase-mediated lip-
olysis of TG-rich plasma lipoproteins (Bijland et al. 2011;
Pouwer et al. 2019). These processes appear to contribute to
the lowered blood TG levels but also to the enhanced hep-
atic TG concentrations in PFOS/PFOA-treated rodents.
PPARa is also known to play a role in cholesterol homeo-
stasis, including inhibition of cholesterol and bile acid synthe-
sis in mice and man) (Post et al. 2001; Li and Chiang 2009),
regulation of HDL metabolism and promotion of reverse
cholesterol transport (Li and Glass 2004; Ory 2004; Li and
Chiang 2009). Nevertheless, the role of PPARa in the PFAS-
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induced changes on blood and liver cholesterol in rodents is
still elusive. This is further discussed in Section 3.4.
Although the general view remains that the PPARa plays a
pivotal role in PFOS/PFOA-induced lipid disturbances in rats
and mice (ATSDR 2018; EFSA CONTAM Panel 2018a), some
evidence suggests its role is of less importance. Actually, the
effects observed upon PFOS/PFOA exposure are not per se
consistent with effects of other well-studied PPARa activators,
such as fibrates and Wyeth (WY)-14643. For example, typical
PPARa activators commonly do not cause liver steatosis in
rodents at comparable doses and exposure durations (Larter
et al. 2012; Pawlak et al. 2015), contrary to what is seen after
exposure to PFOS/PFOA.
Some information from PPARa-null mice studies further
support the notion for the involvement of PPARa-independ-
ent pathways in the PFOS/PFOA-exerted lipid disturbances.
However, it is important to emphasize that knocking out the
receptor itself in mice affects lipid metabolism, leading to
steatosis in the liver of control PPARa-null mice (Howroyd
et al. 2004; Corton et al. 2014; Das et al. 2017), which might
interfere with the interpretation of the results obtained for
PFOS/PFOA treated PPARa-null mice. Still, it has been shown
that PPARa-null mice exhibit hepatic lipid accumulation and/
or alterations in genes linked to lipid metabolism upon
exposure to PFOA (Rosen, Abbott, et al. 2008; Rosen, Lee, et
al. 2008; Minata et al. 2010; Nakagawa et al. 2012; Das et al.
2017) or PFOS (Rosen et al. 2010), which counterargues that
these effects should be attributed to PPARa activation.
Nakagawa et al. (2012), for example, demonstrated that the
liver steatosis in the PFOA-exposed PPARa-null mice is more
prominent when compared to the WT mice (1 and 5mg/kg
bw/d, 6weeks). In that study, control PPARa-null mice
showed only a slight and not statistically significant increase
in hepatic TG accumulation, contrary to what is commonly
seen with such knock-out animals (Howroyd et al. 2004;
Corton et al. 2014; Das et al. 2017). Overall, data on PFOA-
exposed PPARa-null mice seem to corroborate the contribu-
tion of other PPARa-independent signaling pathways in the
lipid disturbances induced by PFOS/PFOA in rodents.
3.2.3. Are PPARa-mediated effects in rodents relevant for
human health?
The importance of the PPARa receptor in human liver has
been questioned in the past, due to the perceived low
expression of PPARa in humans and minimal responsiveness
of human liver cell lines to PPARa activation (Tugwood et al.
1996; Auboeuf et al. 1997; Palmer et al. 1998). Accordingly,
the potential human relevance of the PFOS/PFOA-induced
lipid perturbations seen in rodents, and, at least partially,
driven by activation of the PPARa pathway, has been subject
to debate (DWQI 2017, 2018; EFSA CONTAM Panel 2018a).
However, later research indicates that the quantitative
expression of PPARa is similar in human and mouse liver
(Kersten and Stienstra 2017) and that in human hepatocytes
and liver slices, PPARa is able to effectively induce the
expression of genes involved in numerous lipid metabolic
pathways. Still, remains to a lesser extent compared to
mouse or rat hepatocytes and mouse liver slices (Okyere
et al. 2014; Corton et al. 2014; Janssen et al. 2015; Liss and
Finck 2017; Heusinkveld et al. 2018). Indeed, studies using
chimeric mice, harboring murine as well as human hepato-
cytes in the liver, underscore the more modest PPARa-medi-
ated gene trans-activation in human hepatocytes compared
to their murine counterparts (de la Rosa Rodriguez et al.
2018). Apart from these quantitative interspecies differences,
qualitative differences have also been illustrated recently,
after comparisons of PPARa signaling transcriptional net-
works in primary human hepatocytes and rats (McMullen
et al. 2020). Such differences could in principle result in dif-
ferential responses in humans and rats when exposed to
PPARa-ligands.
With respect to the activation of the human PPARa
(hPPARa) by PFOS/PFOA, studies with hPPARa expressing
mice suggest a lower response to PFOA, when compared to
their WT counterpart. This is seen by lower increase in tran-
scripts and protein levels of PPARa target genes (Nakamura
et al. 2009; Nakagawa et al. 2012). Still, in combination with
these gene expression changes, PFOA-treated hPPARa mice
showed increased lipid accumulation in liver (Nakagawa et al.
2012; Schlezinger et al. 2020). Actually, despite the reduced
responsiveness of hPPARa to PFOA, hPPARa mice appeared
to be substantially more susceptible to liver steatosis than
the WT mice, as shown by larger increases in hepatic TG lev-
els (Nakagawa et al. 2012). This further supports that the
PFOA-induced liver steatosis, specifically the increase in TG
levels, might be driven by PPARa-independent pathways.
With respect to cholesterol, blood levels remained unaffected
by the treatment in hPPARa mice, contrary to the WT mice
that showed the typical decrease, when exposed to PFOA.
Similar studies with PFOS have not been identified in
the literature.
The activation of the hPPARa by PFOA, but also PFOS, was
likewise seen with in vitro assays performed in human liver
cells, such as human primary hepatocytes, or human liver cell
lines (HepG2 and HepaRG) (Bjork et al. 2011; Beggs et al.
2016; Behr et al. 2020; Louisse et al. 2020). These studies sup-
port the activation of PPARa signaling, at concentrations
commonly ranging from 10mM to 100 mM (PFOA:
4000–40 000 ng/mL, PFOS: 5000–50 000 ng/mL). These
concentrations are high when compared directly to the
serum levels recorded even at the highly exposed popula-
tions or at workers in occupational settings. However, in one
study, gene expression network analysis showed a simulation
of the PPARa signaling already at a concentration of 1 mM for
PFOA (Buhrke et al. 2015). As seen in vivo for PFOA, in vitro
studies comparing responses upon PFOS/PFOA exposure
between rodent and human primary hepatocytes support the
view that induction of PPARa transcriptional responses are
more pronounced in rodent than in human hepatocytes
(Bjork and Wallace 2009; Bjork et al. 2011).
As already stressed for rodents, some in vitro studies have
demonstrated differences with respect to the hPPARa activa-
tion potency between PFOS and PFOA. Again, PFOA seems a
more potent activator of the hPPARa than PFOS in reporter
gene assays (Takacs and Abbott 2007; Wolf et al. 2008; 2012),
but also in gene expression studies with human hepatocytes
(Bjork et al. 2011; Buhrke et al. 2015; Louisse et al. 2020).
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These differences can be also related to the differences in
cellular uptake. For example, cellular uptake of the PFASs in
HepG2 cells was shown to be low for PFOA (0.24%), but 10-
fold lower for PFOS (0.04%) (at a concentration of 10 mM,
10% serum), with absolute cellular concentrations of 39 and
4nmol/mg protein for PFOA and PFOS, respectively
(Rosenmai et al. 2018). In that study, PFOA induced PPARa-
mediated reporter gene expression at relatively high concen-
trations (30 and 100 mM) whereas PFOS did not induce
PPARa-mediated reporter gene expression, possibly reflecting
the differences in cellular uptake, but perhaps also in PPARa
affinity. However, preliminary data on human HepaRG cells
(own unpublished data) indicate the reverse, i.e. PFOS accu-
mulating more in the cells than PFOA. To our knowledge,
data on cellular uptake of PFASs are currently very limited. It
should be emphasized here that overall the lack of informa-
tion on this aspect is an important limitation of these in vitro
data. Such measurements would in principle assist in more
appropriate comparisons on actual exposure levels, since the
nominal concentrations applied in the in vitro systems might
not be a good proxy for serum levels. As such it is difficult to
assess at this state whether the effective concentrations
in vitro are relevant for human exposure.
3.2.4. Conclusions
The role of PPARa activation by PFOA in the observed lipid
perturbations in rodents, but also its relevance for human
health, has been extensively studied, including examinations
in hPPARa and PPARa-null mice, and in rodent and human
hepatocytes. For PFOS less data are available. Overall, PFOA
and to a lesser extent PFOS activate PPARa, both its murine
and human version, and the observed lipid alterations may
depend to a certain extent on the PPARa-signaling pathway.
Effects on PPARa-null mice indicate, however, the involve-
ment of other pathways. With respect to the human situ-
ation, the large differences in exposure scenarios when
compared to rodents, combined with the reduced hPPARa
responsiveness to PFOS/PFOA, warrant the need for careful
consideration when comparing rodent and human findings. It
cannot be excluded that in humans higher exposure is
required for the manifestation of the effects on lipid metab-
olism, but it should be stressed that certain PFASs accumu-
late to a higher extent in humans than in rats and mice (see
Section 4 on toxicokinetics). As such, due to the life-long
exposure of humans to such substances, along with high
exposure rates, a certain critical body burden necessary to
affect lipid homeostasis by this pathway might be achieved.
3.3. Other nuclear receptors potentially involved in
PFOS/PFOA-mediated lipid disturbances
3.3.1. PXR, CAR and other signaling pathways
As discussed above, it is suggested that PPARa-independent
signaling pathways are also involved in the lipid disturbances
induced by PFOS/PFOA. In particular the transactivation of
other nuclear receptors by PFOS/PFOA, such as PPARc, con-
stitutive androstane receptor (CAR), pregnane X receptor
(PXR), liver X receptor (LXR) and farsenoid X receptor (FXR),
have been studied in rats and mice. It has been suggested
that the nuclear receptors PPARc (Rosen, Lee, et al. 2008),
CAR (Rosen, Lee, et al. 2008; Ren et al. 2009; Abe et al. 2017;
Schlezinger et al. 2020) and PXR (Ren et al. 2009; Bjork et al.
2011; Pouwer et al. 2019), are also activated by PFOS/PFOA
in the murine liver. These receptors are in general associated
with cholesterol and TG homeostasis (Ory 2004; Yin et al.
2011; Yan et al. 2015), implying that they might also play a
role in the effects induced by PFOS/PFOA. Considering that
gene expression is rarely dependent on a sole transcription
factor, and that cross-talk between various transcription fac-
tors is known to occur, PFOS/PFOA effects in rodents are
probably a result of multiple inter-linked pathways.
In vitro studies with human relevant material reported
somewhat contradicting results, which could also be the out-
come of variable experimental designs, i.e. different concen-
trations, exposure durations, cell systems etc. In human
primary hepatocytes (Bjork et al. 2011), in HepaRG (Abe et al.
2017) and in HepG2 cells (Zhang et al. 2017), multiple nuclear
receptors (CAR, PXR, LXR) were activated by PFOS and PFOA,
as illustrated by increased expression in some selected
marker genes. Yet, other gene expression studies in human
hepatocytes and/or reporter gene assays have shown that
PFOS/PFOA may activate to a very limited (if any) extent all
these receptors, including PPARc and FXR (Vanden Heuvel
et al. 2006; Buhrke et al. 2015; Behr et al. 2020; Louisse et al.
2020). Louisse et al. (2020) compared the effects of PFOS/
PFOA on gene expression in HepaRG cells with the effects of
a known LXR-agonist and a FXR-agonist (data from Wigger
et al. 2019), suggesting that PFOS/PFOA do not activate these
receptors.
3.3.2. Disruption of HNF4a signaling pathway by
PFOS/PFOA
Amongst the other nuclear receptors, of particular interest is
the hepatocyte nuclear factor HNF4a, that seems to be
affected by PFOS/PFOA (Yan et al. 2015; Beggs et al. 2016;
Pouwer et al. 2019). HNF4a is considered a master regulator
of liver-specific gene expression and essential for liver devel-
opment and liver function, including lipid homeostasis
(Hayhurst et al. 2001; Yin et al. 2011; Yeh et al. 2019).
Dysregulation of HNF4a function has been associated with a
large number of human diseases, including nonalcoholic fatty
liver disease (Yeh et al. 2019). There is cross-talk between
HNF4a and other nuclear receptors like PPARa, for which
both antagonism and synergism have been reported
(Chamouton and Latruffe 2012; Lu 2016). There is also evi-
dence for inhibitory cross-talk between PXR and HNF4a as
well as CAR and HNF4a in hepatic lipid metabolism. While
HNF4a is a transcriptional activator of CYP7A1, the rate-limit-
ing enzyme in bile acid biosynthesis, PPARa and PXR inhibit
CYP7A1 expression, probably by competing with HNF4a for a
common transcriptional coactivator (Li and Chiang 2005;
Miao et al. 2006). Similarly, CAR downregulates HNF4a target
genes (Miao et al. 2006). Repression of CYP7A1 results in
decreased transformation of cholesterol into bile acids (see
Section 3.4.2), leading to lipid accumulation in the liver and
increased LDL-C levels in humans (Laskar et al. 2017).
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In studies with mice, PFOS and PFOA exerted reduction in
the HNF4a protein expression (10 and 3mg/kg bw/d, respect-
ively), after a short, i.e. 7-day exposure, while HNF4a mRNA
levels were not affected (Beggs et al. 2016). Upon a longer
exposure to PFOA (1.25 and 5mg/kg bw/d, 28 days), HNF4a
mRNA levels were slightly decreased; still, this reduction of
the transcription factor was not reflected in representative
target genes (Yan et al. 2015). In the humanized APOE3-
Leiden.CETP mouse, the expression of HNF4a mRNA was
mildly increased after treatment with a similar dose, i.e.
3.2mg/kg bw/d (serum levels 90 000 ng/mL at 4weeks),
whereas in silico prediction of transcription factor activity
based on the expression changes of known target genes was
decreased (Pouwer et al. 2019).
Data from in vitro assays with human cells exposed to
PFOS/PFOA also point toward a downregulation of the
HNF4a pathway. A proteomic study with human HepG2
cells (Scharmach et al. 2012) showed inhibition of HNF4a
signaling upon exposure to 25 mM of PFOA (10 000 ng/mL).
Such effects were also seen in primary human hepatocytes
after a 96-h treatment with PFOS or PFOA (Beggs et al.
2016), with protein levels of HNF4a (but not mRNA levels)
decreasing at the highest concentration tested (10 mM;
4000 ng/mL). PFOA-induced inhibition of HNF4a in pri-
mary human hepatocytes was also observed in another
study, albeit at higher concentrations (25 and 100 mM;
10 000–42 000 ng/mL) (Buhrke et al. 2015). In human
HepaRG cells, Behr et al. (2020) reported a downregulation
of HNF4a gene expression at concentrations of 50 mM and
above after a 24- or 48-h exposure. In another HepaRG
study, HNF4A was not significantly downregulated by
100mM PFOS/PFOA, but expression of CYP7A1 was
decreased (Louisse et al. 2020).
3.3.3. Conclusions
In conclusion, there is evidence indicating the involvement of
other nuclear receptors important in lipid homeostasis, such
as PXR, in the PFOS/PFOA-induced lipid dysregulation in
rodents. With respect to human liver cells, such data are lim-
ited and hence, their relevance for the potential induced lipid
perturbations by PFOS/PFOA in humans, is not clear.
Regarding the HNF4a pathway there are some indications
that it might be involved in potential effects of PFOS/PFOA
on cholesterol and lipid homeostasis. However, this evidence
is not so strong and more investigations are required to
potentially support this mechanism. In addition, it remains
unclear whether in reality PFOS/PFOA exposures result in
serum levels at which suppression of the HNF4a pathway is
likely to occur. More in vitro studies on primary human hepa-
tocytes and liver cell lines would help elucidate this further.
3.4. Mechanisms linked to disturbance of cholesterol
homeostasis
3.4.1. Cholesterol biosynthetic pathway and hepatic uptake
Regarding PFOS/PFOA-induced changes in cholesterol
observed in humans, it is of interest to also consider a
possible direct effect on the intrahepatic cholesterol
biosynthetic pathway, and/or perturbation on its import to/
export from the liver. In the liver, regulation of cholesterol
levels is achieved through a negative feedback mechanism,
in which hepatic cholesterol accumulation suppresses its de
novo synthesis, and concurrently, the liver’s uptake of chol-
esterol from the blood (Brown and Goldstein 1997;
Feingold 2000; DeBose-Boyd 2008). The expression of
genes that are involved in de novo cholesterol synthesis,
but also uptake, is under control of the hepatic transcrip-
tion factor sterol regulatory element-binding proteins
(SREBP) (Horton et al. 2002; Jeon and Osborne 2012; Shao
and Espenshade 2012). Amongst these genes are the
HMGCR (3-hydroxy-3-methyl-glutaryl (HMG)-coenzyme A
reductase), encoding the rate-limiting enzyme of the chol-
esterol biosynthetic pathway (converts HMG-CoA to meval-
onate; Figure 3), as well as the gene encoding the LDL
receptor (LDLR). The LDLR is the main receptor involved in
cholesterol uptake from the blood to the liver via endo-
cytosis, and its activity regulates the plasma levels of chol-
esterol (Brown and Goldstein 1997). SREBP stimulates in
parallel the hepatic cholesterol synthesis and clearance
from the blood and thus, the balance between these two
processes determines ultimately the levels of cholesterol in
the liver and serum circulation (Brown and Goldstein 1997;
Horton et al. 2002). Cholesterol export from the liver into
the circulation occurs via the VLDL particles, which are
metabolized into LDL-C in the blood.
Exposure to high PFOS/PFOA doses has been demon-
strated to decrease the hepatic VLDL-TG and apoB produc-
tion in the liver of the APOE3-Leiden.CETP mouse
concomitantly with enhanced lipoprotein lipase-mediated
VLDL clearance (Bijland et al. 2011; Pouwer et al. 2019),
resulting in decreased cholesterol and TG levels in serum. In
these studies with the APOE3-Leiden.CETP mouse, hepatic
accumulation of cholesterol and TGs was only seen upon
PFOS exposure and not with PFOA (see Sections 3.1.2).
There are some reports on the effect of PFOS/PFOA on
intrahepatic cholesterol synthesis, as well as on hepatic
cholesterol uptake from the bloodstream. In murine liver,
PFOA and PFOS were shown to enhance SREBP activity, as
indicated by an increased expression on both the tran-
scriptional and protein level. In parallel, a significant upre-
gulation of relevant target genes, such as HMGCR and
LDLR, was detected (Rosen et al. 2010: 10mg/kg bw/d,
7 days; Yan et al. 2015: 1.25–20mg/kg bw/d, 4 weeks).
However, histopathological examinations did not reveal
hepatic lipid accumulation in the case of PFOS (Rosen
et al. 2010), while total hepatic cholesterol levels were
reduced after PFOA exposure (Yan et al. 2015). In contrast
to the two aforementioned studies, others reported
reduced expression of certain SREBP target genes, accom-
panied by elevated intrahepatic cholesterol levels. In rats,
both PFOS/PFOA lowered hepatic cholesterol synthesis, as
reflected by a reduced activity of liver HMGCR enzyme
(Haughom and Spydevold 1992) or mRNA levels (Guruge
et al. 2006: 5mg/kg bw/d, 3 weeks). Similarly, the expres-
sion of HMGCR and LDLR was decreased by PFOA in both
WT and hPPARa mice (Schlezinger et al. 2020: 0.7 mg/kg b/
d, 6 weeks). Despite the lowered expression of the
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biosynthetic genes, exposures to PFOS or PFOA led to a
pronounced hepatic cholesterol accumulation. These data
imply that increased intrahepatic cholesterol, as seen in
rodents after exposure to PFOS/PFOA, might not be dir-
ectly related to de novo cholesterol biosynthesis. Instead,
the effects could be the consequence of other impaired
pathways, such as the secretion as VLDL particles (Section
3.1.2) and/or cholesterol metabolism into bile acids
(Section 3.4.2).
In vitro results with human cells pertaining to affected
genes involved in cholesterol synthesis and PFOS/PFOA
seem to be somewhat inconsistent. Using a human fetal
liver cell line (L-02), Peng et al. (2013) combined a gene
expression and metabolomics analysis, and reported an
effect of PFOA on cholesterol biosynthesis. Measurement
of cholesterol suggested a concentration-dependent
increase in intracellular levels (significant at the high con-
centration: 120 mM, 72 h). In addition, several cholesterol
biosynthesis genes were upregulated at the same concen-
tration. Opposing to these findings, Behr et al. (2020)
reported a downregulation of such genes (e.g. HMGCR,
SQLE, and LDLR) and the transcription factor SREBP in
HepaRG cells after 24 or 48 h, at concentrations 10 and
25 mM for PFOA and PFOS, respectively. Intracellular chol-
esterol levels were not affected. Similar results were
obtained for PFOA and PFOS in a recent transcriptomics
study with HepaRG cells (Louisse et al. 2020; 100 mM, 24 h),
showing a downregulation of gene sets related to choles-
terol biosynthesis and SREBP signaling. In primary human
hepatocytes, PFOA induced a concurrent upregulation
(e.g. MVK: mevalonate kinase, PMVK: phosphomevalonate
kinase) and downregulation (e.g. SQLE, FDFT1: farnesyl-
diphosphate farnesyltransferase 1) of few cholesterol bio-
synthesis genes, whereas most remained unaffected
(Buhrke et al. 2015; 100 mM, 24 h).
3.4.2. Intrahepatic disturbances in the enterohepatic cycle
and bile acid formation
Another possible explanation for the PFOS/PFOA-induced
changes in blood and liver cholesterol is perturbation of bile
acid synthesis from cholesterol. Excess cholesterol in the liver
is stored, exported or converted into bile acids; the predom-
inant pathway in human liver is the classic bile acid synthesis
pathway, which is initiated by the rate-limiting enzyme chol-
esterol 7-alpha hydroxylase (CYP7A1) (Princen et al. 1997;
Chiang 2017). The enzyme’s gene expression and the bile
acid synthesis rate are inhibited by bile acids, which return to
the liver through the enterohepatic circulation (Thompson
1996; Chiang 1998; Li and Chiang 2009). Hence, an elevated
hepatic re-uptake of bile acids induces a negative feedback
loop via the farnesoid X receptor (FXR) to lower the de novo
synthesis of bile acids from cholesterol, by CYP7A1 inhibition.
Alterations in serum bile acid levels suggest either a direct
disruption of the bile acid flow or/and a disturbance of the
intrahepatic bile acid synthesis from cholesterol
(Thompson 1996).
In rats, PFOS/PFOA have been shown to increase the lev-
els of serum bile acids (PFOS at 2.5 and PFOA at 5mg/kg
bw/d) after a 28-day exposure (NTP 2019a, 2019b). In
APOE3-Leiden.CETP mice, PFOS, inhibited bile acid excretion
in the feces (Bijland et al. 2011: 3mg/kg bw/d, 4–6weeks). In
addition, downregulation of hepatic CYP7A1 gene expression
upon exposure to PFOS (Bijland et al. 2011; Wang et al. 2014:
5mg/kg bw/d, 2weeks) or PFOA (Pouwer et al. 2019;
Schlezinger et al. 2020) was seen. These findings show
impairment of the bile flow and synthesis, through which
PFOS/PFOA may affect cholesterol homeostasis. It should be
noted that next to the FXR the main transcription factors reg-
ulating CYP7A1 include HNF4a and PPARa (Chen et al. 2001;
Kir et al. 2012), which have already been suggested as
Figure 3. The principal steps of the hepatic cholesterol biosynthetic pathway. HMGCS1: HMG-CoA synthase 1; HMGCR: HMG-CoA reductase. HMGCS1 catalyzes the
condensation of acetyl-CoA with acetoacetyl-CoA to HMG-CoA. In a following step HMG-CoA is converted by HMGCR to mevalonate. Subsequently, several enzym-
atic reactions are required for the synthesis of cholesterol. SQLE: Squalene epoxidase. SQLE catalyzes the first oxygenation step in sterol biosynthesis. CYP7A1: chol-
esterol 7-alpha hydroxylase. CYP7A1 catalyzes the transformation of excess cholesterol into bile acids. Created with BioRender.com.
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molecular target of PFOS and PFOA (see Sections Section 3.2
and Section 3.3).
Reduction of CYP7A1 expression has been also demon-
strated in vitro, in human hepatocytes (Beggs et al. 2016:
10mM, 96 h) and in HepaRG cells (Behr et al. 2020: 10 mM,
48 h; Louisse et al. 2020: 100mM, 24 h).
Interference of PFOS/PFOA with the enterohepatic cycling
may also play a role. PFOS/PFOA have been shown to be
excreted in the bile (Harada et al. 2007; Fujii et al. 2015), and
thereafter, are believed to be substantially re-absorbed from
the gastrointestinal tract (see Section 4). Both substances
have been reported to share the same transporters (e.g.
NTCP: Naþ/taurocholate co-transporting polypeptide, ASBT:
apical sodium-dependent bile salt transporter, OATPs: organic
anion transporting polypeptides) as bile acids for excretion
via bile into the intestine and re-absorption in the ileum
(Zhao et al. 2015, 2017). Therefore, PFOS/PFOA may alter the
absorption of bile acids through competition for the same
transporter, interfering as such with the negative feedback
control of the conversion of cholesterol to bile acids and per-
turbing cholesterol levels. For example, losses of bile acids
are compensated by enhanced bile acid synthesis from chol-
esterol, the mechanism behind the cholesterol lowering
effect of the drug cholestyramine. This resin binds bile acids
in the gastrointestinal lumen to prevent reabsorption and
indirectly lowers serum cholesterol levels via enhanced con-
version of cholesterol to bile acids, which in turn leads to
activation of SREBP-mediated LDLR expression. Interestingly,
in rats application of cholestyramine also strongly increased
the excretion of PFOA via feces (Genuis et al. 2010, 2013).
With respect to the enterohepatic circulation in humans,
differences in the absorption of bile acids due to genetic fac-
tors, food composition or medicines can lead into altered lev-
els of serum cholesterol. For example, dietary fiber intake
was recently reported to be associated with lower PFAS
serum concentrations in humans (Dzierlenga et al. 2020).
Consequently, it is plausible that confounding related to
excretion and re-absorption in the enterohepatic cycling pro-
cess may play a role in the associations for PFOS/PFOA and
total serum cholesterol reported repeatedly in the cross-sec-
tional epidemiological studies. Nevertheless, confounding
due to this biological mechanism is till now only a postula-
tion with no available supporting evidence (see Section 2.1)
(EFSA CONTAM Panel 2020).
3.4.3. Conclusions
Collectively, there are indications that PFOS/PFOA influence
different aspects of cholesterol metabolism, including biosyn-
thesis, import/export from the liver and conversion into bile
acids. Despite this, the molecular events leading to the altera-
tions in serum cholesterol that may be caused by PFOS/PFOA
exposure in animals and humans remain unclear. More
insight into the mechanisms involved is needed in order to
understand the molecular events that are potentially trig-
gered by PFOS/PFOA and how these may ultimately lead to
cholesterol alterations in blood and/or liver. Additionally, it
should be noted once more that for the interpretation of
such findings the exposure levels should be taken into
consideration, which are different between animals and
humans. For interpretation of data from in vitro assays differ-
ence in the free fraction between the in vitro assay and the
in vivo situation has to be considered. Currently, this is hin-
dered by lack of data on the free fraction of PFOS/PFOA in
the medium of different in vitro studies and/or the related
cellular concentrations in in vitro systems.
4 Species differences in toxicokinetic properties of
PFOS and PFOA
Apart from the toxicodynamic differences analyzed above,
toxicokinetic differences have been reported for the PFASs,
with most data on PFOS and PFOA. In general, both chemi-
cals are well absorbed from the intestinal tract and are
excreted unmetabolized (US EPA 2016a, 2016b; ATSDR 2018;
EFSA CONTAM Panel 2018a). Once absorbed, PFOS/PFOA
bind extensively to serum albumin (>90%), as shown in sev-
eral species (Ehresman et al. 2007; Han et al. 2012; Beesoon
and Martin 2015), while also binding to the liver fatty acid
binding protein (L-FABP) has also been reported for the rat
and human (Luebker et al. 2002; Woodcroft et al. 2010).
With regard to organ distribution it is often mentioned
that PFOS/PFOA accumulate in the liver and kidney (EFSA
CONTAM Panel 2018a). However, as shown recently, PFOA
does not deposit preferentially in the liver (NTP 2019b),
based on the average liver:plasma partition coefficient (PC) in
male rats after a 28-day exposure3 (range across doses:
0.87–1.17). This is somewhat lower than what has been previ-
ously shown in other studies in the male rat with a single
PFOA exposure (showing PCs of for example 2.2 and 0.8 at a
low and high dose (Kudo et al. 2007) and 2.3 (Kim et al.
2016). The NTP finding is important considering the repeated
exposure, which is not commonly applied in toxicokinetic
studies. For PFOS current evidence indicates a higher reten-
tion in the liver (Seacat et al. 2003; Curran et al. 2008; NTP
2019a). In this case, the liver: plasma PCs obtained for
example from a 14-week exposure (Seacat et al. 2003) are in
the range of 6.3–12.2 across doses, but lower after shorter
(NTP 2019a: 4weeks, range across doses: 2.74–3.76) and sin-
gle (Kim et al. 2016; mean: 2.6) exposures. With regard to the
kidney, neither of the two substances show accumulation in
the rat, with kidney: plasma PCs of 0.4–1 for PFOA (Kudo
et al. 2007; Kim et al. 2016; Dzierlenga et al. 2020) and
0.3–1 for PFOS (Kim et al. 2016; Huang et al. 2019).
Human data are unfortunately very limited in number
(Olsen et al. 2003; Ericson et al. 2007; Perez et al. 2013). In
order to facilitate a preliminary comparison with the rat data,
human organ:plasma PCs were calculated (Table 3, N ¼ 20)
based on the available information. It should be mentioned
though that for these calculations data of PFOS/PFOA levels
in the tissues and blood plasma do not stem from the same
study (see Table 3, furthermore note the high variability of
organ measurements), i.e. they come from different persons;
they are, however, from the same region. The results suggest
a substantial higher distribution to the liver for both PFOA
and PFOS in a substantial part of the human population,
probably reflecting the long human exposure period.
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Calculated kidney:plasma PCs, in humans versus rats, are
comparable for PFOA, whereas PFOS seems to accumulate
more in some human kidneys compared to the rat kidney
(Kudo et al. 2007; Kim et al. 2016; Huang et al. 2019;
Dzierlenga et al. 2020). For the time being, and in the
absence of more information, these data imply that at com-
parable blood concentrations a substantial part of the human
population may have higher intrahepatic levels of PFOS/
PFOA and higher intrarenal PFOS levels when compared
to rodents.
Species differences also exist regarding the elimination
and excretion mechanisms. An overview of the blood ter-
minal half-lives is presented in Table 4, designating much
longer half-lives in humans as compared to rodents and
monkeys. PFOS shows accumulating properties in all species,
with an elimination half-life in the range of a month for the
rat and mouse (20–40 days), and with a remarkable half-life
of  5 years recorded in humans. In the case of PFOS, limited
differences are observed between males and females of the
same species. PFOA also shows high accumulation potential
in many species, except for the rat (0.15–2 days). In addition,
in the rat a remarkable gender difference has been observed
for PFOA, which is briefly discussed below.
In most species, urinary clearance seems to be the primary
elimination pathway (EFSA CONTAM Panel 2018a). For PFOA,
clear differences have been reported between male and
female rats pertaining to the renal elimination and they have
been linked specifically to the active protein-mediated trans-
port that governs tubular secretion and re-absorption (from
the pre-urine back to the kidney and blood circulation) (Han
et al. 2012). Sex-hormone mediated expression of organic
anion transporting polypeptide (Oatp)1a1, located on the
apical tubular membrane, was demonstrated to play a role in
the observed renal re-absorption of PFOA in the male rat
(Yang et al. 2009). However, more transporters, including
organic anion transporters (oats) may be involved (Kudo
et al. 2002). This information provides an explanation on the
observed faster renal excretion of PFOA in female as opposed
to male rats.
Elimination of PFOS/PFOA in humans is thought to be pri-
marily via urinary excretion. However, there is a clear lack of
studies on fecal excretion (EFSA CONTAM Panel 2018a). PFOS
and PFOA are shown to be highly excreted in the bile; still,
most of the quantity excreted into the gut is believed to
undergo extensive enterohepatic re-absorption (>97%)
(Harada et al. 2007; Fuji et al. 2015). Renal re-absorption via
kidney transporters has been demonstrated for PFOS and
PFOA (Nakagawa et al. 2009; Han et al. 2012). Such re-
absorption processes, both renal and intestinal, are believed
to contribute substantially to the observed long elimination
half-lives of both PFOS and PFOA in humans.
Overall, from a kinetic perspective there are species- (and
gender)-dependent differences, primarily regarding the terminal
half-life, intra-hepatic and intra-renal concentrations and excre-
tion patterns for PFOS/PFOA. These differences further compli-
cate the extrapolation of rodent data to the human situation.
Kinetic differences have to be carefully considered prior to such
extrapolations, by scaling of rodent data to humans and vice
versa. For risk assessment purposes it is important to consider
body burdens or serum levels rather than the exposure levels.
Toxicokinetic modeling, based on available data from animal
and human studies, may provide a better basis for such extrapo-
lations. In vitro kinetic studies may also provide insight into the
various input parameters for such models. It is emphasized here
that with regard to the in vitro toxicity assays toxicokinetics are
also very important to consider, prior to extrapolations of effect-
ive doses to humans. A direct comparison of the nominally
applied concentration of PFOS/PFOA in vitro with the respective
human PFOS/PFOA blood levels is not necessarily a good
approach. Given that in vitro and in vivo exposure situations dif-
fer fundamentally, extrapolations from these cell systems to
humans are complex and shall not be performed without inte-
gration of the kinetic aspects.
Conclusions and recommendations
Many epidemiological studies have shown associations
between increased blood levels of PFOS/PFOA and increased
Table 3. PFOS/PFOA organ concentrations in humans and calculated human organ:plasma partition coefficients (based on mean/
median organ concentrations).
Organ concentrations (ng/mL)
Calculated human organ:plasma partition coefficients
(mean, median, or range, accordingly)
PFOA PFOS PFOA PFOS
Blood 1.80 ± 0.66a 7.64 ± 3.54c
1.65b 7.60b
Plasma† 3.2 ± 1.2a 13.6 ± 6.3a 1 1
Liver‡ 4.0b 41.9b 1.3 3.1
3–98.9c 3–405c 0.9–30.9 0.2–29.8
Brain‡ <LOD (¼2.45) 1.9b Not available 0.1
3–22.5c 0.2–1.6
Lung‡ 12.1b 28.4b 3.8 2.1
6–87.9c 3–61.8c 1.9–27.5 0.1–2.0
Kidney‡ 1.5b 55b 0.5 4.0
3–11.9c 3–369c 0.9–3.7 0.2–27.1
Ericson et al. (2007), N¼ 48, age: 55. 5 ± 5.5 years.
†Fabrega et al. (2014), applying a 0.56 blood !plasma conversion while ignoring erythrocyte binding.
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blood total cholesterol, and in some cases TGs. Exposure to
the substances have occurred for several decades.
Nonetheless, many of these studies are cross-sectional and
consequently, the extent to which the relationships between
PFOS/PFOA exposure and these altered levels of blood lipids
are causal remains uncertain. Also, there are no associations
with related adverse outcomes, like CVD. Even so, given the
very small changes in the involved risk factors, such effects
could be possibly detected only in very large studies. The
recorded associations could also be the result of confounding
related to excretion and re-absorption in the enterohepatic
cycling process of PFOS/PFOA and bile acids, which can
affect serum cholesterol levels. However, until now this
remains only a postulation that requires experimen-
tal evidence.
Intriguingly, studies with shorter durations and high expo-
sures of PFOS/PFOA in rodents and in some cases monkeys,
have demonstrated opposite effects, i.e. decreased serum
cholesterol and TGs. Such effects occur at much higher (at
least >100-fold) serum levels and are commonly accompa-
nied by enhanced intrahepatic lipid (mainly TG) concentra-
tions. This complicates the interpretation of the human
findings. In order to support (or not) a causal inference and
to elucidate whether such findings are a real health concern
for humans, a clear mechanistic understanding relevant for
humans is essential.
Mechanistic evidence discussed in this manuscript stems
from studies performed primarily with rodents and with
human liver-derived cells. In rodents, most of the studies
focus on the role of PPARa, and its activation by PFOS/PFOA
appears to play, at least partially, a role in PFOS/PFOA-
induced lipid perturbations, but it is not the sole mechanism.
With respect to humans, studies in hPPARa mice demon-
strate a reduced responsiveness of the human PPARa to
PFOA when compared to rodents. The same is recorded for
both PFOS/PFOA in human liver cells. This, together with the
large differences in exposure levels and durations between
animals and humans, indicates that comparisons between
rodent and human findings shall be done with caution. Also,
other pathways that do not directly involve PPARa seem to
play a role in the PFOS/PFOA-induced lipid disturbances, as
shown in rodents and rodent-derived hepatocytes. These
relate to the activation of other nuclear receptors important
for lipid homeostasis, such PXR and CAR. Nonetheless, studies
with PFOS/PFOA on human hepatocytes indicate contradict-
ing results, rendering the relevance of these receptors for
humans uncertain. A possible role of these receptors remains
to be clarified.
In addition, available data suggest that the effect of PFOS/
PFOA on cholesterol and lipid homeostasis may also be
mediated via suppression of the HNF4a pathway.
Furthermore, there are indications that PFOS/PFOA may
affect the cholesterol levels, by interfering with its metabol-
ism and specifically its transformation into bile acids (includ-
ing interference with CYP7A1), as well as the transport of the
latter. Such observations are indeed valuable for better
understanding of the mode of action, but they require fur-
ther elucidation. In summary, the underlying mechanism of
PFOS/PFOA-induced lipid disturbances seems to be rather
complex and hitherto, not fully delineated.
Similarly, there is no simple mechanistic explanation for
the differences in findings between animals and humans. The
discrepancy in effects between rodents and humans may be
related to profound interspecies differences in physiology
regarding lipid homeostasis, and/or PFAS-species differences
in toxicokinetics, as well as basic nutrition. These differences
and potential interpretations are discussed throughout the
manuscript (summarized in Figure 4).
The explanation for the observed differences in health
effects in rodents versus humans may also lie with the
large differences in exposure levels and durations between
animals and humans. Cholesterol and TG changes in
humans are recorded after chronic exposure and at serum
concentrations of PFOS/PFOA at least two to three orders
of magnitude lower, when compared to the respective
serum concentrations in rodents. This is mainly due to the
Table 4. Information of terminal half-lives for PFOS and PFOA in various species.
Substance
Species/terminal half-life
Rat Mouse Pig Monkey Humans
PFOS 27.8 days (m)
24.8 days (f)
(Kim et al. 2016)
42.8 days (m)
37.8 days (f)
(Chang et al. 2012)
634 days
(Numata et al. 2014)
132 days (m)
110 days (f)
(Chang et al. 2012)
Occupational workers:
5.4 years
(Olsen and Zobel 2007)
Community
(contaminated drinking
water): 3.4 years (Li
et al. 2020)
PFOA 1.6–1.8 days (m)
0.15–0.19 days (f)
(Kim et al. 2016)
21.7 days (m)
15.6 days (f)
(Lou et al., 2009)
236 days
(Numata et al. 2014)
21 days (m)
30 days (f)
(Butenhoff et al. 2004)
Occupational workers:




2.3 years (Bartell et al.




water): 2.7 years (Li
et al. 2020)
Source: taken from RIVM (2018) and complemented with more recent data.
m: males; f: females.
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higher doses commonly used for the performance of the
animal studies, while animal studies using low doses,
resulting in serum PFOS/PFOA levels that are comparable
to the human situation, are scarce. One single 4-week
study using more relevant exposure levels in APOE3-
Leiden.CETP mice showed recently that environmental
(approximately 50 ng/ml) or occupational (approximately
1500 ng/ml) levels of PFOA exposure, representative for
exposed community populations and fluorochemical pro-
duction workers respectively, did not increase plasma
cholesterol and TG levels, whereas exposure to high PFOA
levels (90 000–150 000 ng/ml) did decrease TGs, total chol-
esterol and non-HDL-C levels and increased HDL-C level
(Pouwer et al. 2019). This is in accordance with the slight
reduction in cholesterol reported for cancer patients
exposed for 6 weeks to very high PFOA levels (Convertino
et al. 2018), although the interpretation of these data is
difficult due to some methodological issues (see Section
2.1). Perhaps at such high serum levels and such exposure
durations, both in humans and animals, different pathways
come into play, than at the much lower concentrations
and longer exposure durations observed in background
populations and even in areas with increased exposure.
Therefore, there are indeed few indications that the dis-
crepancy in findings between humans and rodents might
be the result of the large differences in exposure condi-
tions. Nevertheless, it must be highlighted that PFOS/
PFOA accumulate much more in humans than in rodents,
as illustrated by the terminal half-lives measured in occu-
pational workers and a highly exposed population (Table
4). In addition, human data (although limited) suggest
that at comparable blood concentrations humans may
have higher intrahepatic levels of PFOS/PFOA and higher
intrarenal PFOS levels when compared to rodents. The life-
long exposure of humans to PFOS/PFOA could possibly
lead to continuously elevated body burdens, sufficient to
cause effects on lipid homeostasis. Overall, it appears that
the interpretation of the existing rodent data on PFOS/
PFOA-induced lipid perturbations, with respect to the
human situation, is complex.
In the case of the in vitro experiments with human hepa-
tocytes, only single short exposures are generally used,
attempting to mimic effects occurring in vivo after repeated
chronic exposures. In addition, only nominal concentrations
applied into the cell cultures are reported, whereas actual
intracellular concentrations are rarely reported. These nom-
inal concentrations in the culture medium are commonly
much higher, when compared directly to serum PFOS/PFOA
levels associated with increased cholesterol and TGs in
humans. However, it is unclear whether these PFOS/PFOA
in vitro concentrations constitute an appropriate surrogate
for serum levels, especially considering the very high pro-
tein binding of these compounds. Quantitative in vitro to
in vivo extrapolations (QIVIVE) would assist in translating
effect levels observed in the in vitro test systems into the
equivalent human PFOS/PFOA serum levels. This shall be
Figure 4. Summarized human- and rodent-specific differences related to PFOS/PFOA exposure, as well as species-specific differences with respect to lipoprotein
metabolism and nutrition. CETP: cholesteryl ester transfer protein; LDL: low-density lipoprotein; HLDL: high-density lipoprotein; TGs: triglycerides; PPARa: peroxisome
proliferator-activated receptor a; PXR: pregnane X receptor; CAR: constitutive androstane receptor; PPARc: peroxisome proliferator-activated receptor c (Created
with BioRender.com.
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done with the integration of kinetics, while preferably the
cellular uptake of the chemicals shall be determined
experimentally.
An important new asset to delineate the species differen-
ces and the inherent differences in signaling pathways
between rodents and humans is to make use of mice with a
humanized chimeric liver (Tateno et al. 2004). In these mice
>80% of the mouse hepatocytes are replaced by human
hepatocytes. The chimeric mice exhibit a “humanized” circu-
lating lipoprotein cholesterol profile with an LDL-C/HDL-C
ratio similar to that observed in humans, as well as bile acid
regulation more characteristic of humans (Ellis et al. 2013).
Importantly, with respect to the substantial species differen-
ces in PPARa expression and the affinity of PFOS/PFOA for
the PPARa receptor, the expression levels of human PPARa
are similar as in humans and their interaction with other rele-
vant transcription factors have a human context. The same
applies to other relevant biological processes. These mice
have been used to elucidate the discrepancy in circulating
cholesterol induced by obeticholic acid, an FXR-agonist and
clinical candidate for treatment of NASH, between rodent
models and humans, where obeticholic acid increased LDL-C
in humans and consistently reduced total cholesterol levels
in rodents (Papazyan et al. 2018). Studies with these mice,
and importantly with different escalating exposure levels rele-
vant to humans, may help elucidate the mechanism of action
of PFOS/PFOA relevant for humans.
Together with studies on chimeric mice, further in vitro
investigations with human hepatocytes may help clarify the
pathway underlying the potential PFOS/PFOA-induced lipid
perturbations. Specifically, more information is needed on
the involvement of the HNF4a signaling pathway, as well as
interference of PFOS/PFOA with cholesterol transformation
into bile acids. Still, given the specific limitations of such
in vitro models, the extrapolation of the effects to humans
shall be done carefully by taking into consideration the dos-
ing and integrating the kinetic aspects. The latter can be
achieved with the use of physiologically based kinetic model-
ing, together with measurements of the actual intracellular
concentrations of the compounds. If such studies are fine-
tuned to the human situation and interpreted in the context
of the intact human, they can generate valuable information
that will contribute to a better understanding of PFAS-medi-
ated lipid perturbations and the issues involved in their inter-
pretation for human health risk assessment.
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Notes
1. EFSA CONTAM Panel has considered four PFASs members for the cal-
culation of a TWI: PFOS, PFOA, PFHxS (perfluorohexanesulfonic acid)
and PFNA (perfluorononanoic acid) (EFSA CONTAM Panel 2020).
2. One decade in human life would correspond to approximately 12
weeks for the rat considering its two-year life span.
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